About: Antibody therapies for the prevention and treatment of viral infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibody therapies for the prevention and treatment of viral infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibody therapies for the prevention and treatment of viral infections
Creator	An, Zhiqiang Fu, Tong-Ming Salazar, Georgina Zhang, Ningyan
Source	Medline; PMC
abstract	Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.
has issue date	2017-07-10(xsd:dateTime)
bibo:doi	10.1038/s41541-017-0019-3
bibo:pmid	29263875
has license	cc-by
sha1sum (hex)	d4798a48149f9f99e2140e596a4246b15d05fd50
schema:url	https://doi.org/10.1038/s41541-017-0019-3
resource representing a document's title	Antibody therapies for the prevention and treatment of viral infections
has PubMed Central identifier	PMC5627241
has PubMed identifier	29263875
schema:publication	NPJ Vaccines
resource representing a document's body	covid:d4798a48149f9f99e2140e596a4246b15d05fd50#body_text
is schema:about of	named entity 'SPECIFICITY' named entity 'CHARACTERIZATION' named entity 'HEALTH CONCERNS' named entity 'EVOLVE' named entity 'TARGETS' named entity 'VIRAL ANTIGENS' named entity 'UNIQUE' named entity 'HUMAN CYTOMEGALOVIRUS' named entity 'INTERACTION' named entity 'RECENT' named entity 'VIRAL PATHOGENESIS' named entity 'CURES' named entity 'MONOCLONAL ANTIBODIES' named entity 'THEIR' named entity 'REVIEW' named entity 'HUMAN USE' named entity 'DRUG' named entity 'HOST' named entity 'specificity' named entity 'viral pathogens' named entity 'monoclonal antibodies' named entity 'TREATMENT' named entity 'MORE THAN' named entity 'HAVE' named entity 'PHYSICIANS' named entity 'IMPORTANT' named entity 'VIRAL' named entity 'COMPONENT' named entity 'CLINICAL EVALUATION' named entity 'RECOMBINANT' named entity 'VIRAL PATHOGENS' named entity 'PATHOGENS' named entity 'RESEARCHERS' named entity 'ANTIBODY THERAPIES' named entity 'PREVENTION' named entity 'VIRAL INFECTIONS' named entity 'PUBLIC HEALTH' named entity 'MATURATION' named entity 'NEWLY' named entity 'ANTIBODIES' named entity 'KNOWN' named entity 'LONG' named entity 'IDENTIFICATION' named entity 'EBOLA' named entity 'YEARS' named entity 'POTENTIAL' named entity 'DISEASE' named entity 'VIABLE' named entity 'CONSIDERED' named entity 'HIGHLY' named entity 'MODALITY' named entity 'UNDERSTAND' named entity 'SUITABLE' named entity 'INFECTIOUS DISEASE' named entity 'QUEST' named entity 'HEIGHTENED' named entity 'MECHANISMS' named entity 'DEVELOPMENT' named entity 'HERE' named entity 'PROCESS' named entity 'THERAPEUTIC' named entity 'SPECIFIC' named entity 'INCLUDING' named entity 'IMMUNE RESPONSES' named entity 'PIPELINE' named entity 'VIRAL INFECTION' named entity 'HIGH' named entity 'modality' named entity 'quest' named entity 'specific' named entity 'potential' named entity 'maturation' named entity 'developed' named entity 'long' named entity 'host' named entity 'mechanisms' named entity 'antibodies' named entity 'Antibodies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software